113 related articles for article (PubMed ID: 11331039)
1. Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b.
Deisenhammer F; Reindl M; Berger T
J Interferon Cytokine Res; 2001 Mar; 21(3):167-71. PubMed ID: 11331039
[TBL] [Abstract][Full Text] [Related]
2. Discordant effect of IFN-beta1a therapy on anti-IFN antibodies and thyroid disease development in patients with multiple sclerosis.
Monzani F; Meucci G; Caraccio N; Saviozzi M; Casolaro A; Moscato G; Lombardo F; Mosti S; Scagnolari C; Bruschi F; Antonelli G; Ferrannini E; Murri L
J Interferon Cytokine Res; 2002 Jul; 22(7):773-81. PubMed ID: 12184915
[TBL] [Abstract][Full Text] [Related]
3. Epitope specificity of neutralizing antibodies against IFN-beta.
Gneiss C; Reindl M; Berger T; Lutterotti A; Ehling R; Egg R; Deisenhammer F
J Interferon Cytokine Res; 2004 May; 24(5):283-90. PubMed ID: 15153311
[TBL] [Abstract][Full Text] [Related]
4. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.
Pungor E; Files JG; Gabe JD; Do LT; Foley WP; Gray JL; Nelson JW; Nestaas E; Taylor JL; Grossberg SE
J Interferon Cytokine Res; 1998 Dec; 18(12):1025-30. PubMed ID: 9877445
[TBL] [Abstract][Full Text] [Related]
5. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies.
Deisenhammer F; Reindl M; Harvey J; Gasse T; Dilitz E; Berger T
Neurology; 1999 Apr; 52(6):1239-43. PubMed ID: 10214750
[TBL] [Abstract][Full Text] [Related]
8. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG).
Rudick RA; Simonian NA; Alam JA; Campion M; Scaramucci JO; Jones W; Coats ME; Goodkin DE; Weinstock-Guttman B; Herndon RM; Mass MK; Richert JR; Salazar AM; Munschauer FE; Cookfair DL; Simon JH; Jacobs LD
Neurology; 1998 May; 50(5):1266-72. PubMed ID: 9595973
[TBL] [Abstract][Full Text] [Related]
9. Measured neutralizing titers of IFN-beta neutralizing antibodies (NAbs) can depend on the preparations of IFN-beta used in the assay.
Files JG; Hargrove D; Delute L; Cantillon M
J Interferon Cytokine Res; 2007 Aug; 27(8):637-42. PubMed ID: 17784815
[TBL] [Abstract][Full Text] [Related]
10. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients.
Cook SD; Quinless JR; Jotkowitz A; Beaton P;
Neurology; 2001 Sep; 57(6):1080-4. PubMed ID: 11571337
[TBL] [Abstract][Full Text] [Related]
11. Persistency of Neutralizing Anti-Interferon-β Antibodies in Patients with Multiple Sclerosis Treated with Subcutaneous Interferon-β Depends on Antibody Titers, IgG Subclasses, and Affinity Maturation.
Dujmovic I; Hegen H; Paz P; Croze E; Deisenhammer F
J Interferon Cytokine Res; 2017 Jul; 37(7):317-324. PubMed ID: 28418769
[TBL] [Abstract][Full Text] [Related]
12. The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients.
Gibbs E; Oger J
J Neuroimmunol; 2007 Oct; 190(1-2):146-50. PubMed ID: 17825927
[TBL] [Abstract][Full Text] [Related]
13. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of an interferon-beta1a product.
Kauffman MA; Sterin-Prync A; Papouchado M; González E; Vidal AJ; Grossberg SE; Chuppa S; Odoriz B; Vrech C; Diez RA; Ferro HH
Int J Immunopathol Pharmacol; 2011; 24(2):499-504. PubMed ID: 21658324
[TBL] [Abstract][Full Text] [Related]
15. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
Sorensen PS; Koch-Henriksen N; Flachs EM; Bendtzen K
Mult Scler; 2008 Jul; 14(6):837-42. PubMed ID: 18505772
[TBL] [Abstract][Full Text] [Related]
16. Antibodies against interferon-beta in multiple sclerosis.
Aarskog NK; Marøy T; Myhr KM; Vedeler CA
J Neuroimmunol; 2009 Jul; 212(1-2):148-50. PubMed ID: 19467718
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive.
Myhr KM; Ross C; Nyland HI; Bendtzen K; Vedeler CA
Neurology; 2000 Nov; 55(10):1569-72. PubMed ID: 11094118
[TBL] [Abstract][Full Text] [Related]
18. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b.
Rice GP; Paszner B; Oger J; Lesaux J; Paty D; Ebers G
Neurology; 1999 Apr; 52(6):1277-9. PubMed ID: 10214759
[TBL] [Abstract][Full Text] [Related]
19. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
Sorensen PS; Koch-Henriksen N; Ross C; Clemmesen KM; Bendtzen K;
Neurology; 2005 Jul; 65(1):33-9. PubMed ID: 15888603
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of four different assays for the detection of binding antibodies against interferon-beta.
Gneiss C; Brugger M; Millonig A; Fogdell-Hahn A; Rudzki D; Hillert J; Berger T; Reindl M; Deisenhammer F
Mult Scler; 2008 Jul; 14(6):830-6. PubMed ID: 18535018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
